novo nordisk oral semaglutide Company of the year 2023: – Riding the wave Oral Semaglutide Demonstrates Greater Weight

2 Less than 1% of patients in an efficacy and safety trial reported a skin adverse event

In a clinical trial called SUSTAIN-6, Semaglutide was shown to significantly reduce the risk of major adverse cardiovascular events, such as heart attack and stroke, in individuals with type 2 diabetes who were at high risk for cardiovascular disease

Current data does not suggest a meaningful difference

At week 68, mean weight loss with CagriSema was approximately 20.4% under the treatment-policy estimand (up to ~22.7% under the trial-product estimand) versus roughly 14.9% with semaglutide, 11.5% with cagrilintide, and 3.0% with placebo

When should I not take Male Excels desiccated thyroid